China saw $28.5 billion invested in its life sciences sector in 2020, which was double the previous year’s amount and sets a five-year high. Partnering activities and IPOs also grew exponentially over the last five years to set records.
Twenty years after the first, exclusively white human genomes were fully sequenced, science finds itself in the same position as the rest of society: with the uncomfortable realization that old inequalities are often morphing, rather than disappearing.
Heidelberg, Germany-based Affimed NV described its progress at the American Association for Cancer Research meeting and discussed the research in a conference call on 2020 financial results, adding fuel to investor enthusiasm for the firm’s natural killer (NK) cell approach, although the update did not come without some confusion.
New and updated preclinical and clinical data presented by biopharma firms at the American Association for Cancer Research Annual Meeting 2021, including: Adagene, Antengene, Ascentage, Beigene, Bluebird, Celcuity, Celldex, Eli Lilly, Geneleap, Greenwich, Heat, Immunocore, Immunogen, Innovent, Psioxus, Replimune, Sotio, Sound, Spectrum, SQZ, Sumitomo, Synthekine, Tachyon, Taiho, Tallac, TCR2, Theratechnologies, Treovir, Trisalus, Ultimovacs, Vincerx, Xencor, Y-mabs, Zentalis, Zymeworks.
Speaking during the 2021 China Pharmaceutical Innovation 100 Summit, industry insiders called for more regulatory talent and even an organizational revamp to clear innovative products faster and support the global development strategies of Chinese drugmakers.
SHANGHAI – China’s regulatory environment has evolved to encourage drug innovation, but despite remarkable progress, mounting pricing pressure from the government and a weak insurance sector remain as barriers.
New and updated preclinical and clinical data presented by biopharma firms at the American Association for Cancer Research Annual Meeting 2021, including: BMS, Kronos, Kymera, Medicenna, Medigene, Mei, Mersana, Mirati, Molecular Partners, Molecular Templates, Morphic, Nextcure, Nuvalent, Oasmia, Oncolytics, Oncomyx, Oncurious, Oncternal, Oric, Pharmabcine, Phio, Pieris, PMV, Puretech, Schrodinger, Seneca.
New and updated preclinical and clinical data presented by biopharma firms at the American Association for Cancer Research Annual Meeting 2021, including: Achilles, Advaxis, Affimed, Agenus, Alpine, Amphivena, Amunix, Arch, Arcus, Bayer, Beigene, Bio-Path, Black Diamond, Briacell, C4, Cardiff Oncology, Checkmate, Clovis, Codiak, Crispr, Elevation, Eli Lilly, Essa, F-star, Fusion, Gennao, Genprex, Glycomimetics, Gracell, GT, Hookipa, Hummingbird, Mirati, Instil, Intra-Cellular, Immune-Onc, Immunogen, Iteos, Jubilant, Kezar, Kineta, Kintara.